Results presented today at the American College of Rheumatology in Boston show that a 12-biomarker test did a better job of predicting radiographic progression in patients with RA. The study ...
The 12-biomarker test is gaining acceptance among rheumatologists and was recently added to a clinical guideline. Starting Sunday, Crescendo Bioscience will present a series of abstracts on its Vectra ...
Crescendo Bioscience®, Inc. has announced the online publication of results validating the performance of Vectra™ DA to measure rheumatoid arthritis (RA) disease activity in Arthritis Care & Research, ...
SALT LAKE CITY, Utah, June 10, 2014 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that Vectra® DA data will be featured in eight posters at ...
Myriad Genetics, Inc.'s ( MYGN) subsidiary, Crescendo Bioscience has published a new study for its Vectra DA blood test in the Annals of the Rheumatic Diseases online journal. The study is a ...
Myriad Genetics, Inc. 's MYGN subsidiary, Crescendo Bioscience continues to make development with its Vectra DA assay. After last week's announcement of its contract with United Rheumatology on this ...
SALT LAKE CITY, Utah, Nov. 19, 2014 - Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today presented new data that showed Vectra® DA is a better predictor of ...
CareFirst BlueCross BlueShield has teamed up with Myriad Genetics to evaluate a multibiomarker rheumatoid arthritis blood test. The 18-month study will assess whether Vectra DA delivers better ...
Dec 27 (Reuters) - Myriad Genetics Inc : * Crescendo Bioscience-vectra da better than clinical inflammatory biomarkers to predict response to non-biological therapy intensification versus anti-tnf ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results